MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas
Part of paid clinical trials in Birmingham, Alabama.
- Sponsor
- SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
- Study ID
- NCT03962543
- Phase
- PHASE2
- Status
- Active Not Recruiting
Conditions
- Neurofibromatosis Type 1 (NF1)
- Plexiform Neurofibroma
Eligibility Criteria
- Sex
- ALL
- Age
- 2 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Mirdametinib (PD-0325901) oral capsule or dispersible tablet — DRUGMirdametinib (PD-0325901) capsule or dispersible tablet
Study Details
This study evaluates mirdametinib (PD-0325901) in the treatment of symptomatic inoperable neurofibromatosis type-1 (NF1)-associated plexiform neurofibromas (PNs). All participants will receive mirdametinib (PD-0325901). Eligible participants may continue in a long-term follow-up phase.
Key Dates
- First listed
- May 24, 2019
- Start date
- Sep 29, 2019
- Status verified
- Jun 2026
- Primary completion
- Sep 20, 2023
- Completion
- Dec 22, 2028
Study Design
- Enrollment
- 114 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Mirdametinib (PD-0325901)Mirdametinib (PD-0325901) capsule or dispersible tablet 2 mg/m\^2 (maximum dose of 4 mg) by mouth twice daily
Primary Outcome Measure
Confirmed Objective Response Rate at the End of the Treatment Phase. [ Time Frame: Up to 24 months ]
Locations (43)
Find similar trials in Birmingham, AL
By research site
University of Alabama at Birmingham/Children's of Alabama· Birmingham, ALMayo Clinic Arizona· Phoenix, AZArkansas Children's Hospital· Little Rock, ARChildren's Hospital Los Angeles· Los Angeles, CAUniversity of California, Los Angeles (UCLA)· Los Angeles, CAChildren's Hospital of Orange County· Orange, CA
Related Studies
- Selumetinib for the Prevention of Plexiform Neurofibroma Growth in NF Type 1PHASE2 · Recruiting · University of Alabama at Birmingham · Birmingham, Alabama
- Study of Cabozantinib With Selumetinib for Plexiform NeurofibromasPHASE1 · Not Yet Recruiting · Girish Dhall, MD · Birmingham, Alabama
- PAS-004 in Adults Who Have Neurofibromatosis Type 1 With Plexiform NeurofibromasPHASE1 · Recruiting · Pasithea Therapeutics Corp. · Birmingham, Alabama
- Neurofibromatosis Type 1 Tumor Early Detection StudyRecruiting · David Miller · Boston, Massachusetts